Table of Contents
ISRN Hematology
Volume 2011 (2011), Article ID 404057, 3 pages
http://dx.doi.org/10.5402/2011/404057
Case Report

Coexistence of Plasma Cell Dyscrasia with Prefibrotic Stage of Primary Myelofibrosis: A Case Report

1Department of Haematology, University Hospital of Heraklion, 71110 Heraklion Crete, Greece
2Department of Nephrology, University Hospital of Heraklion, 71110 Heraklion Crete, Greece

Received 18 February 2011; Accepted 24 March 2011

Academic Editors: Frederick W. Quelle and Jean-Luc Villeval

Copyright © 2011 George Tsirakis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Meerkin, Y. Ashkenazi, S. Gottschalk-Sabag, and C. Hershko, “Plasma cell dyscrasia with marrow fibrosis. A reversible syndrome mimicking agnogenic myeloid metaplasia,” Cancer, vol. 73, no. 3, pp. 625–628, 1994. View at Google Scholar · View at Scopus
  2. W. G. McCluggage, F. G. Jones, D. Hull, and H. Bharucha, “Sclerosing IgA multiple myeloma,” Acta Haematologica, vol. 94, no. 2, pp. 98–101, 1995. View at Google Scholar · View at Scopus
  3. L. Vandermolen, L. Rice, and E. C. Lynch, “Plasma cell dyscrasia with marrow fibrosis. Clinicopathologic syndrome,” American Journal of Medicine, vol. 79, no. 3, pp. 297–302, 1985. View at Google Scholar · View at Scopus
  4. B. S. Kasimis, R. Yen-Lin, and R. S. Neiman, “Multiple myeloma associated with myelofibrosis. Report of a case and literature review,” Oncology, vol. 38, no. 6, pp. 369–372, 1981. View at Google Scholar · View at Scopus
  5. G. Leone, F. Scuderi, M. Carlesimo, and F. Crivelli, “Myelofibrosis associated with IgG myeloma,” Acta Haematologica, vol. 67, no. 2, pp. 139–140, 1982. View at Google Scholar · View at Scopus
  6. J. P. Stevenson, R. Schwarting, and S. J. Schuster, “Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis,” American Journal of Hematology, vol. 59, no. 1, pp. 79–82, 1998. View at Google Scholar · View at Scopus
  7. T. Buhr, G. Büsche, H. Choritz, F. Länger, and H. Kreipe, “Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens,” American Journal of Clinical Pathology, vol. 119, no. 1, pp. 152–158, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. A. Georgii, G. Buesche, and A. Kreft, “The histopathology of chronic myeloproliferative diseases,” Bailliere's Clinical Haematology, vol. 11, no. 4, pp. 721–749, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Thiele and H. M. Kvasnicka, “Prefibrotic chronic idiopathic myelofibrosis—a diagnostic enigma?” Acta Haematologica, vol. 111, no. 3, pp. 155–159, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. G. Barosi, A. Ambrosetti, C. Finelli et al., “The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia,” British Journal of Haematology, vol. 104, no. 4, pp. 730–737, 1999. View at Google Scholar · View at Scopus
  11. E. J. Baxter, L. M. Scott, P. J. Campbell et al., “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders,” The Lancet, vol. 365, no. 9464, pp. 1054–1061, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. C. James, V. Ugo, J. P. Le Couédic et al., “A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera,” Nature, vol. 434, no. 7037, pp. 1144–1148, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. R. Kralovics, F. Passamonti, A. S. Buser et al., “A gain-of-function mutation of JAK2 in myeloproliferative disorders,” The New England Journal of Medicine, vol. 352, no. 17, pp. 1779–1790, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. L. Levine, M. Wadleigh, J. Cools et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis,” Cancer Cell, vol. 7, no. 4, pp. 387–397, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. R. L. Krzyzaniak, D. H. Buss, M. R. Cooper, and H. B. Wells, “Marrow fibrosis and multiple myeloma,” American Journal of Clinical Pathology, vol. 89, no. 1, pp. 63–68, 1988. View at Google Scholar · View at Scopus
  16. M. Urashima, A. Ogata, D. Chauhan et al., “Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells,” Blood, vol. 87, no. 5, pp. 1928–1938, 1996. View at Google Scholar · View at Scopus
  17. M. Portier, X. G. Zhang, E. Ursule et al., “Cytokine gene expression in human multiple myeloma,” British Journal of Haematology, vol. 85, no. 3, pp. 514–520, 1993. View at Google Scholar · View at Scopus
  18. L. M. Scott, P. J. Campbell, E. J. Baxter et al., “The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders,” Blood, vol. 106, no. 8, pp. 2920–2921, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. W. H. Raskind, R. Jacobson, S. Murphy, J. W. Adamson, and P. J. Fialkow, “Evidence for the involvement of B lymphoid cells in polycythemia vera and essential thrombocythemia,” Journal of Clinical Investigation, vol. 75, no. 4, pp. 1388–1390, 1985. View at Google Scholar · View at Scopus
  20. N. S. Majhail and A. E. Lichtin, “Rare coexistence of multiple myeloma with essential thrombocythemia: report of two cases,” Haematologica, vol. 88, no. 4, article ECR09, 2003. View at Google Scholar